Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State#845723
• A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers#800243
• A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants#884615
• A Single Dose Study Of PF-04620110 In Healthy Subjects#876732
• Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation#982663